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Abstract
Purpose Specific overexpression of cholecystokinin 2
(CCK2)/gastrin receptors has been demonstrated in several
tumours of neuroendocrine origin. In some of these cancer
types, such as medullary thyroid cancer (MTC), a sensitive
diagnostic modality is still unavailable and therapeutic
options for inoperable lesions are needed. Peptide receptor
radionuclide therapy (PRRT) may be a viable therapeutic
strategy in the management of these patients. Several
CCK2R-targeted radiopharmaceuticals have been described
in recent years. As part of the European Union COSTAction
BM0607 we studied the in vitro and in vivo characteristics of
12 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA)-conjugated CCK2R binding peptides. In the present
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study, we analysed binding and internalization character-
istics. Stability, biodistribution and imaging studies have
been performed in parallel by other centres involved in the
project.
Methods Determination of IC50 values was performed
using autoradiography, with DOTA-peptides displacing
125I-CCK from receptors on tissue sections from human
tumours. Saturation binding and internalization experiments
were performed using 111In-labelled peptides. The rat
AR42J cell line and the human A431-CCK2R transfected
cell line were utilized for in vitro experiments; dissociation
constants (Kd) and apparent number of binding sites (Bmax)
were determined. Internalization was determined in
receptor-expressing cells by incubating with tracer amounts
of peptide at 37 and 4°C for different times up to 120 min.
Surface-bound peptide was then stripped either by acid
wash or subsequent incubation with 1 μM unlabelled
peptide at 4°C.
Results All peptides showed high receptor affinity with
IC50 values ranging from 0.2 to 3.4 nM. Saturation
experiments also showed high affinity with Kd values in
the 10−9–10−8 M range. Bmax values estimated in A431-
CCK2R cells ranged from 0.6 to 2.2×106 per cell. All
peptides showed high levels of internalization when
incubated at 37°C.
Conclusion All DOTA-conjugated peptides showed high
receptor binding and internalization properties and appear
suitable for further characterization, as described in other
articles of this issue.
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Introduction
A number of cell surface receptor systems are being
evaluated in order to develop peptide-based radiopharma-
ceuticals for diagnostic and therapeutic purposes in
oncology [1]. Many of these receptor systems have been
shown to be overexpressed in certain types of human
cancers. Naturally occurring ligands for tumour-expressed
receptors are often small peptides that can be readily
radiolabelled and utilized for in vivo targeting. An excellent
example of the successful clinical application of this
approach has been the use of radiolabelled somatostatin
analogues in a number of clinical studies on imaging and
targeted radionuclide therapy of cancers that overexpress
specific somatostatin receptor subtypes. Using peptides
labelled with 111In and 68Ga, single photon emission
computed tomography (SPECT) and positron emission
tomography (PET) imaging of disease has been performed
and afterwards therapy was applied using the same
compounds labelled with β-emitters such as 90Y or 177Lu.
The cholecystokinin (CCK) family of receptors contains
two major CCKR subtypes, CCK1R and CCK2R (also
referred to as CCKAR and CCKBR or gastrin receptor,
respectively). Overexpression of these receptor subtypes has
been demonstrated in certain human tumours [2]. The
CCK1R has been found to be overexpressed in a number
of pancreatic adenocarcinomas as well as in cell lines
derived from such tumours and to a smaller extent in
gastroenteropancreatic (GEP) tumours. The CCK2R has
been found to be overexpressed in >90% of medullary
thyroid cancers (MTC) as well as in other tumours of
neuroendocrine origin.
Development of CCK2R targeting radiopharmaceuticals
for imaging and radionuclide therapy has gained great
interest as there is an unmet demand for effective treatment
options for this disease when in an advanced stage [3]. A
number of CCK and gastrin derivatives showing high
affinity for the CCK2R have been characterized over the
past years for the purpose of in vivo receptor targeting for
imaging and therapy. Béhé and Behr have evaluated
diethylenetriaminepentaacetic acid (DTPA)- and 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-
coupled derivatives of minigastrin [4–6]. Peptides based
on the CCK8 sequence have also been evaluated by
different groups [7, 8]. von Guggenberg et al. have
evaluated cyclized forms of minigastrin in order to improve
stability [9]. Other approaches to improve peptide stability
have been reported by Roosenburg et al. [10]. Mather and
coworkers have recently evaluated and compared a number
of gastrin and CCK derivatives [11], including a modified
divalent gastrin peptide containing two receptor binding
motifs in the same sequence [12]. Derivatives of minigastrin
labelled with 99mTc have recently been evaluated as well
[13] and the first clinical applications showed the great
promise of this approach [14].
Specific targeting to CCK2R has been demonstrated
with most compounds tested to date, but there remain a
number of issues that need improvement, particularly for
therapeutic applications. One major issue encountered in
the development of therapeutic peptides targeting the
CCK2R is the elevated kidney accumulation especially of
gastrin-based analogues, which may cause severe toxicity.
This appeared to be a significant problem with DTPA- and
DOTA-coupled minigastrin analogues applied in the clinic
[15], but co-infusion of polyglutamic acid has been shown
to greatly reduce renal radioactivity accumulation [16]. On
the other hand, kidney accumulation appeared much lower
for CCK derivatives [7, 17] and truncated minigastrin
analogues [18].
As part of a European Union COST project (BM0607:
Targeted Radionuclide Therapy) an effort has been made to
evaluate and compare in a standardized way 12 peptide
derivatives designed for CCK2R targeting with the final
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goal of developing a ligand for clinical radionuclide
therapy. Peptides have been synthesized and shared by
groups throughout Europe and the same groups have
provided know-how and scientific tools aimed at testing
all the peptides using standardized protocols in side by side
comparison studies. This approach should provide conclu-
sive data on which peptides will be selected for further
clinical development.
All peptides have been coupled to the DOTA chelator
which is widely used for applications in targeted radionu-
clide therapy with β-emitting radionuclides such as 90Y or
177Lu. In this initial evaluation we have compared the
biological behaviour of the 111In-labelled derivatives in in
vitro experiments aimed at determining binding affinities
and internalization properties of the peptide analogues in
human tumour tissues and in tumour cells in culture.
Separate manuscripts will focus on stability and metabolism
[19], biodistribution [20] and small animal imaging
properties [21] of the conjugates being presented.
Materials and methods
Peptide conjugates
Peptide synthesis was carried out in different laboratories
taking part in COST Action BM0607. All peptides were
synthesized on a solid support using Fmoc strategy and
coupled to DOTA at the N terminus. Sequences and
molecular weights of the conjugates are reported in Table 1
along with references to previous publications characteriz-
ing the same or similar peptide conjugates. The crude
compounds were purified by preparative reverse-phase
high-performance liquid chromatography (RP-HPLC).
Mass spectral analysis was carried out on matrix-assisted
laser desorption/ionization (MALDI) time of flight (TOF).
The desired compounds were obtained at HPLC purity
higher than 95% and with a final yield between 30 and
40%.
Radiolabelling
Peptide conjugates were dissolved at concentrations
ranging from 50 to 200 μg/ml. The concentration of the
stock solutions was determined using a UV-Vis spectro-
photometer. Extinction coefficients at 280 nm used were
based on tryptophan, tyrosine and cysteine content
(14,060 cm−1 for MGD5, 12,660 cm−1 for sargastrin,
5,690 cm−1 for SA106 and 6,890 cm−1 for the remaining
peptides). Labelling was performed in 0.1 M hydroxye-
thylpiperazine ethanesulfonic acid (HEPES) buffer pH 5.5
at 10 μM peptide concentration incubating the peptide
solution with 111InCl3 (Covidien, Petten, The Netherlands,
37–185 MBq) for 30 min at 95°C. In order to avoid
sulfoxide formation selenomethionine was added (≈ 1,000
times molar excess). When labelling for saturation binding
experiments, 1.5 equivalents of natInCl3 was added and the
final solution incubated again at 95°C for 30 min in order
to obtain structurally homogeneous ligands. This last step
was omitted when labelling for internalization experi-
ments. Radiochemical purity was assessed by thin-layer
chromatography and was always ≥97%.
Measurement of binding affinities by autoradiography
Binding affinity measurements using autoradiography were
performed as previously described [8] in surgically
extracted human tumour tissues selected from previous
experiments to express CCK2 receptors [2]. The peptide
DTyr-Gly-[(Nle28,31)CCK-26-33] was purchased from
Table 1 Amino acid sequences of the peptide conjugates
Name Sequence MW (g/mol) Reference
G-CCK8 DOTA-Gly-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2 1,507.0 [7]
SA106 DOTA-DAsp-Phe(p-CH2SO3H)-HPG-Gly-Trp-HPG-Asp-Phe-NH2 1,482.6 [10]
MG0 DOTA-DGlu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,037.0 [6]
Sargastrin DOTA-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 2,483.6 [26]
MG11 DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,531.0 [6]
APH070 DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,677.8 [11]
PP-F10 DOTA-DGln-DGln-DGln-DGln-DGln-DGln-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,042.9 [27]
PP-F6 DOTA-DGln-DGln-DGln-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,658.7 [27]
PP-F16 DOTA-DGln-DGlu-DGln-DGlu-DGln-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,045.9 -
PP-F11 DOTA-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,048.8 -
Cyclo-MG1 DOTA-cyclo[γ-DGlu-Ala-Tyr-DLys]-Trp-Met-Asp-Phe-NH2 1,455.7 [9]
MGD5 DOTA-Gly-Ser-Cys-(Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2)2 2,782.9 [12]
HPG homopropargyl glycine
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Research Plus, Inc. (Bayonne, NJ, USA) and labelled with
125I (Anawa, Wangen, Switzerland, 2,000 Ci/mmol).
Increasing amounts of unlabelled CCK2R binding DOTA-
peptide conjugates were added to incubation medium
containing fixed concentrations of the 125I-labelled peptide
to generate competitive inhibition curves. Tissue slides
were exposed to Biomax MR films (Kodak) for 1–7 days.
Tissue standards were used as reference for quantification
(Amersham, UK).
Saturation binding experiments in cells
Cell binding assays were performed on A431 cells that had
been stably transfected with the plasmid pCR3.1 containing
the full coding sequence for the human CCK2 receptor
(A431-CCK2R) [7]. Cells were maintained in medium
containing the neomycin analogue G418 at a concentration
of 500 μg/ml. Binding assays were performed on cells that
had been plated at a density of 100,000–200,000 cells/well
in 12-well multi-well plates 2 or 3 days prior to the
experiments. These conditions allowed for the cells to be
almost confluent at the time of the assay. To assess binding
affinity of the different compounds, triplicate wells were
incubated with serial dilutions of labelled conjugate in
culture medium at 4°C for 1 h, with concentrations ranging
from 0.5 to 500 nM. To assess nonspecific binding, binding
curves with the same concentration of labelled peptide in
the presence of 100-fold excess unlabelled peptide were
obtained. Cell-associated radioactivity was recovered from
the wells by trypsinization after two rapid washes in ice-
cold phosphate-buffered saline (PBS). Radioactivity was
then counted, normalized for the number of cells and
nonspecific binding was subtracted. Binding curves were
analysed using GraphPad Prism (version 4.00 for Macintosh,
GraphPad Software, San Diego, CA, USA). Dissociation
constants (Kd) and apparent number of binding sites per cell
(Bmax) were derived by fitting the data to the following
equation:
Bound ¼ Bmax» peptide conjugate½ ð Þ= Kdþ peptide conjugate½ ð Þ:
Cell internalization experiments
Cellular internalization was first determined by comparing
differences in accumulation of the compound incubated
with A431-CCK2R or AR42J cells at 4°C, a temperature at
which most metabolic processes are blocked, and at 37°C,
when all metabolic processes including receptor internali-
zation are active. Cells were incubated with a fixed
concentration of the peptide conjugate (10 nM in culture
medium) at both temperatures for 60 and 120 min. After
120 min of incubation some wells were rinsed with PBS to
remove unbound radioactivity and were subsequently
incubated for an additional hour at 4°C with 1 μM cold
peptide, in order to displace any surface-bound radioac-
tivity. Specific binding was assessed by co-incubating
with a 100-fold molar excess of unlabelled peptide in
parallel wells. Cell-associated radioactivity was recovered
from the wells by trypsinization after two rapid washes in
ice-cold PBS.
In another set of experiments, subconfluent cell cultures
of A431-CCK2R and AR42J were transferred to six-well
plates (about 106 cells/well) 24 h before internalization
experiments. Cells were rinsed twice with 2 ml warm PBS
(pH 7.4) and 1 ml 10−9M 111In-labelled peptides (contain-
ing 100–180 kBq) in RPMI culture medium supplemented
with 20 mM HEPES and 1% bovine serum albumin was
added and incubated in triplicate for 1 h at 37°C. Cellular
uptake was stopped by removing radiopeptides from the
cells and rinsing twice with 2 ml of ice-cold PBS. Cell
surface-bound radioactivity was removed by adding 1 ml of
20 mM sodium acetate in PBS (pH 5.0) and collected after
incubation for 10 min at room temperature, after which
1 ml of 1 M NaOH was added to lyse the cells. The lysates
(internalized fractions) and surface-bound fractions were
counted separately in a gamma counter (Perkin Elmer,
Wallac, 1480 Wizard 3”, Turku, Finland). To test receptor
specificity of internalization, 10−6 M gastrin was added to
the 10−9M radiolabelled CCK/gastrin analogues to compete
with the binding of radiolabelled CCK/gastrin analogues to
the CCK2 receptor and also tested in triplicate (referred to
as “block”). For comparison of uptakes in different cell
lines, counts were expressed as percentage of added
radioactivity per milligram protein of cell lysate, the latter
determined using a commercially available colorimetric
assay (Bio-Rad, Veenendaal, The Netherlands).
Results
Displacement experiments performed with unlabelled
DOTA-peptide conjugates on tissue samples and evaluated
using quantitative autoradiography are reported in Table 2.
All peptide conjugates showed high affinity displacement
of 125I-CCK8 with IC50 values between 10
−10 and 10−9 M.
Saturation binding experiments performed with 111In-
labelled DOTA-peptide conjugates on A431-CCK2R cells
showed saturable binding for all peptides with similar Kd
values in the range of 10−9 and 10−8 M. Accordingly the
apparent number of binding sites per cell was also similar
among different peptides in a range between 0.6 and 2.2×
106 sites per cell (Table 3).
In order to assess and compare the rate and level of
internalization of the different peptide conjugates, experi-
ments were performed incubating cells with small amounts
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of labelled peptide (10 nM) and comparing cell retention at
4 and 37°C, two incubation conditions generally accepted
as having no active internalization of receptor and active
receptor turnover, respectively. These experiments were
conducted independently in two laboratories.
Experiments performed on A431-CCK2R cells showed
progressive accumulation in the cells of all labelled radio-
peptides tested. The rate at which activity in cells increased
over time is shown in Fig. 1a. Values are normalized to the
average maximum amount of radioactivity reached after 2 h
of incubation for each peptide at 37°C. The amount bound
to cells at 4°C (30 min of incubation), which is assumed to
be the starting point for subsequent internalization of
peptide, is set as the 0 min time point. The time course of
cell-associated radioactivity for cells incubated at 4°C over
the 2-h observation period (not shown) showed no
significant increase in uptake over time for all peptides.
After 2 h of incubation with labelled peptide at both
temperatures, cells were incubated with 1 μM unlabelled
peptide in order to displace any surface-bound radioligand
still present. Figure 1b shows that cells previously
incubated at 37°C retained most radioactivity after dis-
placement of surface-bound peptide. Conversely, cells
incubated at 4°C show that most radioactivity was
displaced from the cell surface to background levels with
a certain degree of variability in the residual nonspecific
binding to cells. These results show that internalization of
the peptides occurred for all conjugates tested. The increase
in cell-associated activity for cells grown in internalizing
conditions (37°C) compared to cells where internalization
was inhibited by incubation at 4°C was in the range of 5–20
times at 2 h, suggesting that internalization likely will play
an important role in increasing the amount of radiopeptide
targeted to tumours in vivo.
Figure 2 shows the internalization results obtained in the
second set of internalization experiments. In accordance
with the data shown in Fig. 1, all compounds showed a
high internalization rate in A431-CCK2R cells and AR42J
cells after 60 min incubation (Fig. 2a). Cell-associated
activity was significantly reduced after blockade with
unlabelled gastrin for all compounds, indicating receptor-
specific binding and internalization. One compound (cyclo-
MG1) appeared to show a much lower total uptake in rat
AR42J cells, expressing the rat receptor, than in A431-
CCK2R cells, expressing the human CCK2 receptor
(Fig. 2b).
Discussion
The 12 CCK2R/gastrin binding peptides evaluated appear
to be very similar with regard to receptor binding and
internalization properties. The displacement experiments
performed by quantitative autoradiography showed high
affinity displacement for all peptides tested with IC50
values in the same range as for similar peptides evaluated
Conjugate Kd±SEM (nM) Bmax±SEM (nM) Bmax±SEM sites/cell × 10
6
G-CCK8 15.7±2.9 0.40±0.02 0.8±0.5
SA106 14.6±2.7 0.20±0.01 0.7±0.4
MG0 13.5±2.9 0.83±0.07 1.7±0.2
Sargastrin 13.2±4.6 0.31±0.04 0.6±0.1
MG11 16.0±1.4 0.36±0.01 0.7±0.2
APH070 21.4 ±1.6 1.49±0.05 2.2±0.1
PP-F10 9.4±1.0 0.21±0.06 0.6±0.2
PP-F6 4.8±2.4 0.38±0.06 1.1±0.1
PP-F16 9.0±4.2 0.30±0.04 0.9±0.1
PP-F11 15.9±2.2 1.21±0.06 1.8±0.2
Cyclo-MG1 13.0±1.6 0.42±0.03 1.3±0.1
MGD5 11.5±1.2 2.13±0.08 2.1±0.1
Table 3 Kd and Bmax values
obtained from saturation binding
experiments with 111In-labelled
DOTA-peptide conjugates in
A431-CCK2R cells
Conjugate IC50±SEM (nM,
n in parentheses)
G-CCK8 NP
SA106 1.1±0.35 (3)
MG0 0.4±0.12 (3)
Sargastrin 0.4±0.17 (3)
MG11 1.0±0.42 (3)
APH070 0.6±0.15 (3)
PP-F10 1.1±0.06 (3)
PP-F6 3.4±0.36 (5)
PP-F16 0.6±0.11 (4)
PP-F11 0.5±0.07 (5)
Cyclo-MG1 0.7±0.12 (3)
MGD5 0.2±0.04 (3)
Table 2 IC50 values obtained
with the unlabelled DOTA-
peptide conjugates by
quantitative autoradiography
using human tumour
tissue samples
NP not performed
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using the same method in previous publications [8]. All
the peptides tested have a common Trp-X-Asp-Phe-NH2
motif at the C terminus of the peptide and most have the
Ala-Tyr-Gly triplet immediately to the N-terminal side.
There is structural evidence of a direct interaction of the
Trp-Met sequence of CCK8 with the extracellular portion
between transmembrane domains 6 and 7 of the CCK2
receptor [22]. Given the small differences in the IC50
values derived it appears that these sequences are
important for adequate interaction with the CCK2 receptor
and none of the modifications performed in other areas of
the peptide significantly impact the ability to have high
affinity displacement.
Saturation binding experiments similarly showed Kd
values all within a fairly narrow window of values in the
10−8 M range. The Kd values reported show slightly lower
affinity compared to previously reported values for similar
peptides tested on other cell culture systems or tissue
samples [23], but are comparable to values found for
similar peptide conjugates tested on the same tissue culture
system [7, 24, 25]. The cell culture model in question is the
human A431 epidermoid carcinoma cell line where
Fig. 1 a Time course of
cell-associated activity in
A431-CCK2R cells incubated
at 37°C for the 12 radiopeptides
tested. Uptake values are
normalized to uptake at 120 min
that was set at 100%. b
Displacement of surface-bound
radioactivity by subsequent
addition of unlabelled peptide
(1 μM) after incubation with
radiolabelled peptides for
120 min at 37 and 4°C
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expression of the receptor was obtained by cellular
transfection [7]. Although the human coding sequence
was utilized to transfect these cells, it is conceivable that
some of the post-translational modifications to the protein
are missing in the A431 cells relative to cells of
neuroendocrine origin where the protein is physiologically
expressed. This may contribute to the slightly lower affinity
values observed when using these cells. Nevertheless, given
the high level binding and active internalization properties
displayed by the cells they are an adequate model for
testing binding and internalization properties of CCK2R
peptides.
Indeed, internalization experiments performed using two
different protocols showed a high internalization rate of all
peptides in the CCK2R transfected A431 cell line again
indicating that the differences in the peptide sequences
presented have minimal impact on internalization of the
receptor-peptide complex.
Internalization experiments performed in the rat AR42J
cell line also produced similar results. One exception was
the internalization of cyclo-MG1 (Fig. 2b). In this cell line,
very little specific interaction and internalization was
observed with 111In-DOTA-cyclo-MG1. This may be due
to the differences in the binding domain of the rat versus
Fig. 2 a Comparison of
cell-associated radioactivity,
expressed of % of the total
added radioactivity (% A), for
all 12 radiopeptides after 60 min
incubation at 37°C using
A431-CCK2R cells. Total
uptake is the sum of internalized
fraction and membrane-bound
fraction. b Comparison of
cell-associated radioactivity,
expressed as % of the total
added radioactivity per mg cell
protein (% A/mg protein), for
two radiopeptides after 60 min
incubation at 37°C using
A431-CCK2R cells versus
AR42J cells. Total uptake is the
sum of internalized fraction
and membrane-bound fraction
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the human receptor. It should be noted that this same
peptide analogue coupled to a different chelating system for
labelling with 99mTc [9] was previously characterized in this
same cell line and showed saturable binding with a Kd of
approximately 20 nM in the AR42J cells. The structural
peculiarity of this cyclized peptide, which places certain
conformational constraints on peptide-receptor interaction,
may have contributed to the lower receptor affinity found
for the DOTA-coupled conjugate currently being evaluated
towards the rat receptor.
Conclusion
All peptide conjugates tested showed high affinity binding
and active internalization into CCK2R-expressing cells.
Based on the presented in vitro data there were no
candidates that showed markedly superior properties com-
pared to the others for further clinical evaluation. All
peptide sequences tested appeared suitable for further
characterization as described in the other articles of this
issue [19–21].
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